Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension

Sandeep Sahay, Franck Rahaghi

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Pulmonary arterial hypertension is a progressive disease that can lead to right-sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach.

Original languageEnglish (US)
JournalPulmonary Circulation
Volume10
Issue number1
DOIs
StatePublished - Jan 2020

Keywords

  • chronic thromboembolic pulmonary hypertension
  • pulmonary arterial hypertension
  • pulmonary hypertension
  • riociguat

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this